Anthropogenic climate change is altering the management of production forests. These changes are motivated by the need to adapt to the uncertainties and risks of climate change, and by the need to ...enlist their carbon storage and sequestration capacity as part of global mitigation efforts. These changes do however raise concerns regarding the potential implications for forest biodiversity. Here we evaluate these concerns by assessing the biodiversity implications of climate change adaptation and mitigation strategies (CCAMS) being implemented in the production forests of Sweden. We do so by identifying biodiversity goals aimed specifically at closing the existing gap between the habitat requirements of forest-dependent species, and the conditions provided by production forests, in terms of tree species composition, forest structures, and spatio-temporal forest patterns. We then use the existing literature to determine whether and by which pathway each CCAMS is likely to bridge or extend this gap. Our results indicate that CCAMS will often come into direct or partial conflict with Swedish biodiversity goals in production forests. Furthermore, some CCAMS which are inconsistent with biodiversity goals, such as logging residue removal, are being implemented more extensively than those which were most consistent with biodiversity goals. We nevertheless challenge the necessity of setting the preservation of forest biodiversity against climate change mitigation and adaptation. We clarify how CCAMS with negative biodiversity implications may still be implemented without adverse outcomes, if coupled with conservation interventions, or combined with other CCAMS deemed complementary in habitat provision.
•Climate change adaptation and mitigation strategies are changing forest management.•These changes can conflict with biodiversity goals for production forests.•We develop a framework to assess 7 CCAMS applied to Sweden's production forests.•We found that CCAMS often came into direct or partial conflict with biodiversity goals.•We challenge the need for trade-offs and provide pathways to synergistic outcomes.
We use radial velocities from spectra of giants obtained with the WIYN telescope, coupled with existing chemical abundance measurements of Na and O for the same stars, to probe the presence of ...kinematic differences among the multiple populations of the globular cluster (GC) M13. To characterize the kinematics of various chemical subsamples, we introduce a method using Bayesian inference along with a Markov chain Monte Carlo algorithm to fit a six-parameter kinematic model (including rotation) to these subsamples. We find that the so-called extreme population (Na-enhanced and extremely O-depleted) exhibits faster rotation around the centre of the cluster than the other cluster stars, in particular, when compared with the dominant 'intermediate' population (moderately Na-enhanced and O-depleted). The most likely difference between the rotational amplitude of this extreme population and that of the intermediate population is found to be ~4 km s super( -1), with a 98.4 per cent probability that the rotational amplitude of the extreme population is larger than that of the intermediate population. We argue that the observed difference in rotational amplitudes, obtained when splitting subsamples according to their chemistry, is not a product of the long-term dynamical evolution of the cluster, but more likely a surviving feature imprinted early in the formation history of this GC and its multiple populations. We also find an agreement (within uncertainties) in the inferred position angle of the rotation axis of the different subpopulations considered. We discuss the constraints that these results may place on various formation scenarios.
Intense Saharan dust deposition occurs over large oligotrophic areas in the Mediterranean Sea and in the Tropical Atlantic, and its impact on the biogeochemical functioning of such oligotrophic ...ecosystems needs to be understood. However, due to the logistical difficulties of investigating in situ natural dust events, and due to the inherent limitations of microcosm laboratory experiments, new experimental approaches need to be developed. In this paper, we present a new experimental setup based on large, clean mesocoms deployed in the frame of the DUNE (a DUst experiment in a low-Nutrient, low-chlorophyll Ecosystem) project. We demonstrate that these tools are highly relevant and provide a powerful new strategy to in situ studies of the response of an oligotrophic ecosystem to chemical forcing by atmospheric deposition of African dust. First, we describe how to cope with the large amount of dust aerosol needed to conduct the seeding experiments by producing an analogue from soil collected in a source area and by performing subsequent appropriate physico-chemical treatments in the laboratory, including an eventual processing by simulated cloud water. The comparison of the physico-chemical characteristics of produced dust analogues with the literature confirms that our experimental simulations are representative of dust, aging during atmospheric transport, and subsequent deposition to the Mediterranean. Second, we demonstrate the feasibility in coastal areas to installing, in situ, a series of large (6 × 52 m3) mesocosms without perturbing the local ecosystem. The setup, containing no metallic parts and with the least possible induced perturbation during the sampling sequence, provides an approach for working with the required conditions for biogeochemical studies in oligotrophic environments, where nutrient and micronutrients are at nano- or subnano-molar levels. Two, distinct "seeding experiments" were conducted by deploying three mesocosms serving as controls (CONTROLS-Meso = no addition) and three mesocosms seeded with the same amount of Saharan dust (DUST-Meso = 10 g m−2 of sprayed dust). A large panel of biogeochemical parameters was measured at 0.1 m, at 5 m and 10 m in all of the mesocosms and at a selected site outside the mesocosms before seeding and at regular intervals afterward. Statistical analyses of the results show that data from three mesocosms that received the same treatment are highly reproducible (variability < 30%) and that there is no significant difference between data obtained from CONTROLS-Meso and data obtained outside the mesocosms. This paper demonstrates that the methodology developed in the DUNE project is suitable to quantifying and parameterizing the impact of atmospheric chemical forcing in a low-nutrient, low-chlorophyll (LNLC) ecosystem. Such large mesocosms can be considered as 1-D ecosystems so that the parameterization obtained from these experiments can be integrated into ecosystem models.
Aquaporin 9 (AQP9) is a recently cloned water channel that is permeable to monocarboxylate, glycerol and urea. In rat, AQP9 has been found in testis and liver as well as in brain where its expression ...has been initially shown in glial cells in forebrain. However, the expression of AQP9 has not been investigated in the brainstem. The purpose of this study is to describe the distribution of AQP9-immunoreactive cells throughout the adult rat brain using reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot and immunohistochemistry. We performed immunolabeling on brain from animals perfused with fixative and we show that AQP9 is expressed (i) in astrocytes in the glia limitans, in the white matter and in glial cells of the cerebellum, (ii) in the endothelial cells of pial vessels, and (iii) in specific groups of neurons. The neuronal AQP9 expression was almost exclusively observed in catecholaminergic cells including the adrenergic, noradrenergic and dopaminergic groups, but not in other monoaminergic neurons such as serotonergic or histaminergic cells. A slight labeling was also observed in non-catecholaminergic neurons localized in the paraventricular nucleus of the hypothalamus.
These results indicate that AQP9 has a unique brain distribution with a preferential localization in catecholaminergic nuclei known to be involved in many cerebral functions. While the presence of AQP9 in glia limitans and in endothelial cells of the pial vessels could be related to water transport through the blood–brain barrier, its expression in neuronal cells, not directly involved in the osmoregulation, suggests that brain AQP9 could also be used as a metabolite channel since lactate and glycerol can be energy substrates for neurons.
We present a model for the concurrent formation of globular clusters (GCs) and supermassive stars (SMSs, ≳103M⊙) to address the origin of the HeCNONaMgAl abundance anomalies in GCs. GCs form in ...converging gas flows and accumulate low-angular momentum gas, which accretes on to protostars. This leads to an adiabatic contraction of the cluster and an increase of the stellar collision rate. A SMS can form via runaway collisions if the cluster reaches sufficiently high density before two-body relaxation halts the contraction. This condition is met if the number of stars ≳106 and the gas accretion rate ≳105M⊙ Myr-1, reminiscent of GC formation in high gas-density environments, such as - but not restricted to - the early Universe. The strong SMS wind mixes with the inflowing pristine gas, such that the protostars accrete diluted hot-hydrogen burning yields of the SMS. Because of continuous rejuvenation, the amount of processed material liberated by the SMS can be an order of magnitude higher than its maximum mass. This 'conveyor-belt' production of hot-hydrogen burning products provides a solution to the mass budget problem that plagues other scenarios. Additionally, the liberated material is mildly enriched in helium and relatively rich in other hot-hydrogen burning products, in agreement with abundances of GCs today. Finally, we find a super-linear scaling between the amount of processed material and cluster mass, providing an explanation for the observed increase of the fraction of processed material with GC mass. We discuss open questions of this new GC enrichment scenario and propose observational tests.
Background. There is an urgent need for alternative rescue therapies in invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). We assessed the clinical efficacy and safety ...of the combination of fosfomycin and imipenem as rescue therapy for MRSA infective endocarditis and complicated bacteremia. Methods. The trial was conducted between 2001 and 2010 in 3 Spanish hospitals. Adult patients with complicated MRSA bacteremia or endocarditis requiring rescue therapy were eligible for the study. Treatment with fosfomycin (2 g/6 hours IV) plus imipenem (1 g/6 hours IV) was started and monitored. The primary efficacy endpoints were percentage of sterile blood cultures at 72 hours and clinical success rate assessed at the test-of-cure visit (45 days after the end of therapy). Results. The combination was administered in 12 patients with endocarditis, 2 with vascular graft infection, and 2 with complicated bacteremia. Therapy had previously failed with vancomycin in 9 patients, daptomycin in 2, and sequential antibiotics in 5. Blood cultures were negative 72 hours after the first dose of the combination in all cases. The success rate was 69%, and only 1 of 5 deaths was related to the MRSA infection. Although the combination was safe in most patients (94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload. There were no episodes of breakthrough bacteremia or relapse. Conclusions. Fosfomycin plus imipenem was an effective and safe combination when used as rescue therapy for complicated MRSA bloodstream infections and deserves further clinical evaluation as initial therapy in these infections.
The 30 Doradus star-forming region in the Large Magellanic Cloud is a nearby analog of large star-formation events in the distant universe. We determined the recent formation history and the initial ...mass function (IMF) of massive stars in 30 Doradus on the basis of spectroscopic observations of 247 stars more massive than 15 solar masses (Formula: see text). The main episode of massive star formation began about 8 million years (My) ago, and the star-formation rate seems to have declined in the last 1 My. The IMF is densely sampled up to 200 Formula: see text and contains 32 ± 12% more stars above 30 Formula: see text than predicted by a standard Salpeter IMF. In the mass range of 15 to 200 Formula: see text, the IMF power-law exponent is Formula: see text, shallower than the Salpeter value of 2.35.
Azacitidine (AZA) is approved for the treatment of high-risk chronic myelomonocytic leukemia (CMML) of myelodysplastic (MD) subtype. Data of response rates using the specific response criteria for ...this disease are scarce. The aim of this study was to evaluate the response to AZA in patients diagnosed with CMML from the Spanish Registry of Myelodysplastic Syndromes (MDS) applying the overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) response criteria.
We retrospectively studied 91 patients with CMML treated with at least one cycle of AZA from the Spanish Registry of MDS. As it was a real-world study, the response rate was evaluated between cycle 4 and 6, applying the MDS/MPN response criteria
The overall response rate at cycle 4–6 was 58%. Almost half of the patients achieved transfusion independence and one quarter showed clinical benefit, regardless of the CMML French-American-British (FAB) and World Health Organization (WHO) subtypes and CMML Specific Prognosis Scoring (CPSS) risk groups. Toxicity was higher in the MD-CMML subtype.
In our series, most CMML patients achieved an overall response rate with AZA according to the overlap-MDS/MPN response criteria regardless of the CMML FAB and WHO subtypes and CPSS risk groups. Thus, AZA may also be a treatment option for patients with the myeloproliferative CMML subtype and those with a lower-risk CPSS, but symptomatic.
•Chronicmyelomonocytic leukemia patients treated with azacitidine achieve a highoverall response rate.•Myeloproliferativechronic myelomonocytic leukemia could also benefit of treatment with azacitidine,as the myelodysplastic subtype.•Myelodysplastic/myeloproliferativeresponse criteria also allow to analyze the clinical benefit to azacitidine inchronic myelomonocytic leukemia patients.
High-grade glioma (HGG) is associated with several external and internal stressors that may induce mood alterations at all stages of the disease. Symptoms of depression and anxiety in persons with ...glioma have multifactorial etiology and require active follow-up. We reviewed the literature data on the prevalence, mechanisms likely involved in the etiology of mood alterations in persons with HGG and psychosocial interventions found beneficial in treating these symptoms. We also investigated the prevalence and clinical variables that could increase the risk of depression and anxiety symptoms in a group of patients with HGG at two disease time-points: after surgery, before and 1 year after chemoradiotherapy. Literature findings revealed complex mechanisms underlying these symptoms and highlighted the importance of providing early access to palliative care. Our results show a high rate of anxiety and depression symptoms in the first stage of the disease and increased concomitance of these symptoms at the 1-year follow-up. Depression and anxiety symptoms at 1 year after the end of chemoradiotherapy were associated with the presence of symptoms at the first stage of the disease and tumor progression. Antiepileptic drugs and corticosteroid intake did not increase the risk of depressive and anxious symptoms among patients. Active management of mood alterations is an essential part of the care and contributes to patients’ well-being and quality of life.
Objective
Patients' psychological reactions to multigene cancer panel testing might differ compared with the single‐gene testing reactions because of the complexity and uncertainty associated with ...the different possible results. Understanding patients' preferences and psychological impact of multigene panel testing is important to adapt the genetic counselling model.
Methods
One hundred eighty‐seven unrelated patients with clinical suspicion of hereditary cancer undergoing a 25‐gene panel test completed questionnaires after pretest genetic counselling and at 1 week, 3 months, and 12 months after results to elicit their preferences regarding results disclosure and to measure their cancer worry and testing‐specific distress and uncertainty.
Results
A pathogenic variant was identified in 38 patients (34 high penetrance and 4 moderate penetrance variants), and 54 patients had at least one variant of uncertain significance. Overall, cancer panel testing was not associated with an increase in cancer worry after results disclosure (P value = .87). Twelve months after results, carriers of a moderate penetrance variant had higher distress and uncertainty scores compared with carriers of high penetrance variants. Cancer worry prior to genetic testing predicted genetic testing specific distress after results, especially at long term (P value <.001). Most of the patients reported the wish to know all genetic results.
Conclusions
Our results suggest that patients can psychologically cope with cancer panel testing, but distress and uncertainty observed in carriers of moderate penetrance cancer variants in this cohort warrant further research.
PDF
